Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of -28.91% is 45% below its 5-year average of -20.00%, near the low end of its 5-year range (-41.35%–25.74%).
1135.47% below its 12-month average of -2.34%.
Reported quarterly return on assets; no daily interpolation. Q2 FY2026 (2026-06-30): -9.98%.
RETURN ON ASSETS (ROA)
-28.91%
RETURN ON ASSETS (ROA) AVG TTM
-2.34%
RETURN ON ASSETS (ROA) AVG 3Y
-20.04%
RETURN ON ASSETS (ROA) AVG 5Y
-20.00%
RETURN ON ASSETS (ROA) AVG 10Y
N/A
RETURN ON ASSETS (ROA) AVG 15Y
N/A
RETURN ON ASSETS (ROA) AVG 20Y
N/A
CURRENT VS TTM AVG
-1135.47%
CURRENT VS 3Y AVG
-44.28%
CURRENT VS 5Y AVG
-44.55%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-30.70%
median of 715 covered companies
CURRENT VS SECTOR MEDIAN
+5.83%
vs the sector median at left
Keros Therapeutics, Inc.
Market Cap
$223.55M
Return on Assets (ROA)
-28.91%
TTM Avg
-2.34%
3Y Avg
-20.04%
5Y Avg
-20.00%
Market Cap
$229.29M
Return on Assets (ROA)
-52.33%
TTM Avg
-30.08%
3Y Avg
-42.41%
5Y Avg
-37.62%
Market Cap
$217.61M
Return on Assets (ROA)
-58.10%
TTM Avg
-37.08%
3Y Avg
-28.02%
5Y Avg
-25.91%
Market Cap
$234.28M
Return on Assets (ROA)
-29.12%
TTM Avg
-42.23%
3Y Avg
-51.88%
5Y Avg
-48.35%
Market Cap
$235.40M
Return on Assets (ROA)
-23.80%
TTM Avg
-23.59%
3Y Avg
-108.30%
5Y Avg
-108.30%
Market Cap
$236.14M
Return on Assets (ROA)
-4.22%
TTM Avg
-27.32%
3Y Avg
-24.76%
5Y Avg
-32.27%
Market Cap
$216.06M
Return on Assets (ROA)
-31.94%
TTM Avg
-71.44%
3Y Avg
-59.77%
5Y Avg
-50.19%
Market Cap
$214.64M
Return on Assets (ROA)
25.43%
TTM Avg
5.08%
3Y Avg
-10.27%
5Y Avg
-14.74%
Market Cap
$215.94M
Return on Assets (ROA)
21.17%
TTM Avg
16.86%
3Y Avg
29.92%
5Y Avg
34.25%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Keros Therapeutics, Inc. (KROS) | $223.55M | -28.91% | -2.34% | -20.04% | -20.00% |
| Profound Medical Corp. (PROF)vs › | $229.29M | -52.33% | -30.08% | -42.41% | -37.62% |
| Alector, Inc. (ALEC)vs › | $217.61M | -58.10% | -37.08% | -28.02% | -25.91% |
| Biodesix, Inc. (BDSX)vs › | $234.28M | -29.12% | -42.23% | -51.88% | -48.35% |
| BioAge Labs Inc. (BIOA)vs › | $235.40M | -23.80% | -23.59% | -108.30% | -108.30% |
| MacroGenics, Inc. (MGNX)vs › | $236.14M | -4.22% | -27.32% | -24.76% | -32.27% |
| Prelude Therapeutics Incorporated (PRLD)vs › | $216.06M | -31.94% | -71.44% | -59.77% | -50.19% |
| Compugen Ltd. (CGEN)vs › | $214.64M | 25.43% | 5.08% | -10.27% | -14.74% |
| Anbio Biotechnology Class A Ordinary Shares (NNNN)vs › | $215.94M | 21.17% | 16.86% | 29.92% | 34.25% |
| Niagen Bioscience Inc (NAGE)vs › | $214.24M | 15.00% | 14.43% | -2.68% | -18.26% |
ROA
-28.9%
ROE
-31.7%
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | 25.74% |
| 2024-12-31 | -30.42% |
| 2023-12-31 | -41.35% |
| 2022-12-31 | -34.12% |
| 2021-12-31 | -23.01% |
| 2020-12-31 | -16.84% |
| 2019-12-31 | -112.68% |
| 2018-12-31 | -4.87% |
